This is a prospective, single-arm, clinical study to explore the efficacy and safety of
Axi-cel retreatment in R/R LBCL in Shanghai Ruijin Hospital in China.
R/R LBCL patients who treated with Axi-cel got non-CR or relapsed were eligible for Axi-cel
retreatment in this study. Patients will receive the standard dose of Axi-cel and follow the
standard process. Other related treatment like bridging therapy or combination therapy will
be based on patients status and investigators' decision. The primary endpoint is ORR, the
secondary endpoint is CR, PR, DOR, PFS, OS and AE. A total of 32 patients is planned to be
enrolled in this study. The trial will not go on if nobody got CR or PR in first 6 patients.